4.2 Article

Antisense oligonucleotide therapeutics for iron-sulphur cluster deficiency myopathy

期刊

NEUROMUSCULAR DISORDERS
卷 19, 期 12, 页码 833-836

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.nmd.2009.09.011

关键词

Iron-sulphur cluster deficiency myopathy; ISCU; Antisense oligonucleotide treatment; Morpholino; Phosphorodiamidate morpholino oligonucleotide (PMO); Deep intronic mutation

向作者/读者索取更多资源

Iron-sulphur cluster deficiency myopathy is caused by a deep intronic mutation in ISCU resulting in inclusion of a cryptic exon in the mature mRNA. ISCU encodes the iron-sulphur cluster assembly protein IscU. Iron-sulphur clusters are essential for most basic redox transformations including the respiratory-chain function. Most patients are homozygous for the mutation with a phenotype characterized by a nonprogressive myopathy with childhood onset of early fatigue, dyspnoea and palpitation on trivial exercise. A more severe phenotype with early onset of a slowly progressive severe muscle weakness, severe exercise intolerance and cardiomyopathy is caused by a missense mutation in compound with the intronic mutation. Treatment of cultured fibroblasts derived from three homozygous patients with an antisense phosphorodiamidate morpholino oligonucleotide for 48 h resulted in 100% restoration of the normal splicing pattern. The restoration was stable and after 21 days the correctly spliced mRNA still was the dominating RNA species. (C) 2009 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据